IMMURON (IMRN) vs Longeveron Inc. (LGVN)

IMMURON and Longeveron Inc. are both Biotechnology companies. IMMURON and Longeveron Inc. are of similar size ($9.6M and $9.1M). IMMURON grew revenue faster over the last twelve months: −6.62% against −42.7%. IMMURON has the higher net margin (−262.7% vs −1,977.6%) and the higher return on invested capital (0.00% vs −4,549.0%). Across the 15 metrics below, IMMURON leads on 13 and Longeveron Inc. on 2.

Valuation

Metric IMRN LGVN Biotechnology median
P/E n/m n/m 7.88
P/S n/m 7.43 11.47
P/B n/m 0.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.93 n/m 0.74
EV/Sales (3.50) 0.09 10.73
Earnings yield (1.75%) (352.31%) (28.84%)
Free cash flow yield 0.00% (236.36%) (23.03%)

Profitability

Metric IMRN LGVN Biotechnology median
Gross margin 71.28% 69.76% 65.16%
Operating margin 0.00% (1,992.84%) 0.00%
Net margin (262.71%) (1,977.59%) 0.00%
Free cash flow margin 0.00% (1,755.69%) 0.00%
Return on equity 0.00% (203.61%) (57.72%)
Return on assets 0.00% (145.64%) (49.22%)
Return on invested capital 0.00% (4,549.04%) 0.00%

Growth

Metric IMRN LGVN Biotechnology median
Revenue growth (TTM) (6.62%) (42.74%) 5.64%
EPS growth (last fiscal year) 37.29% 50.76% —
Revenue growth, 5-year CAGR 116.96% (26.60%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMRN LGVN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.17 2.63 4.73
Net debt to EBITDA 2.25 0.20 0.96

Dividend

Metric IMRN LGVN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IMRN LGVN Biotechnology median
Market cap 9.60m 9.12m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack